PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Ohnmacht, A. ; Stahler, A.* ; Stintzing, S.* ; Modest, D.P.* ; Holch, J.W.* ; Westphalen, C.B.* ; Hölzel, L. ; Schübel, M.K. ; Galhoz, A. ; Farnoud, A. ; Ud-Dean, M. ; Vehling-Kaiser, U.* ; Decker, T.* ; Moehler, M.* ; Heinig, M. ; Heinemann, V.* ; Menden, M.P.

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.

Nat. Commun. 14:5391 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Precision medicine has revolutionised cancer treatments; however, actionable biomarkers remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) framework for analysing the molecular and biomarker landscape of randomised controlled clinical trials. OncoBird identifies biomarkers based on single genes or mutually exclusive genetic alterations in isolation or in the context of tumour subtypes, and finally, assesses predictive components by their treatment interactions. Here, we utilise the open-label, randomised phase III trial (FIRE-3, AIO KRK-0306) in metastatic colorectal carcinoma patients, who received either cetuximab or bevacizumab in combination with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI). We systematically identify five biomarkers with predictive components, e.g., patients with tumours that carry chr20q amplifications or lack mutually exclusive ERK signalling mutations benefited from cetuximab compared to bevacizumab. In summary, OncoBird characterises the molecular landscape and outlines actionable biomarkers, which generalises to any molecularly characterised randomised controlled trial.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
16.600
0.000
2
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Folfiri Plus Cetuximab; Consensus Molecular Subtypes; Dna Topoisomerase-i; Subgroup Identification; Wild-type; Microsatellite Instability; Predictive Biomarkers; 1st-line Treatment; Open-label; Chemotherapy
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2041-1723
e-ISSN 2041-1723
Zeitschrift Nature Communications
Quellenangaben Band: 14, Heft: 1, Seiten: , Artikelnummer: 5391 Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Computational Biology (ICB)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-554700-001
G-503800-001
G-553500-001
Förderungen European Research Council (ERC)
Roche Pharma AG, Grenzach, Germany
Almac Ltd, Belfast, UK
Pfizer GmbH, Germany
Merck KGaA, Darmstadt, Germany
European Research Council (ERC) under the European Union
This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 950293, M.P.M.). The clinical study received industrial funding from Merck KGaA, Darm
DOI 10.1038/s41467-023-41011-4
WOS ID 001169709500001
WOS ID 001072382600007
Scopus ID 85169688837
PubMed ID 37666855
Erfassungsdatum 2023-10-18
[➜Korrektur melden]